Case Report

Pediatric Case of Li–Fraumeni Syndrome in Honduras

R. Martínez-Beckerat, 1 C. Alas-Pineda, 1 M. Melgar-Gonzales, 1
B. Mejía-Raudales, 2 N. Andino-Paz, 3 S. Bejarano-Cáceres, 4 and J. Chiang 5

1Hospital Nacional Dr. Mario Catarino Rivas, San Pedro Sula, Cortés 21102, Honduras
2Facultad de Medicina y Cirugía, Universidad Católica de Honduras-Campus San Pedro y San Pablo, San Pedro Sula, Cortés 21102, Honduras
3Universidad Nacional Autónoma Honduras en el Valle de Sula, Escuela Universitaria de las Ciencias de la Salud, San Pedro Sula 21102, Honduras
4Liga Contra el Cáncer de Honduras, San Pedro Sula, Cortés 21104, Honduras
5Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA

Correspondence should be addressed to C. Alas-Pineda; cesar_alas10@hotmail.com

Received 17 October 2020; Accepted 28 December 2020; Published 11 January 2021

Copyright © 2021 R. Martínez-Beckerat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Li–Fraumeni syndrome (LFS) was first reported in 1969 by Frederick Li and Joseph Fraumeni; hence, the name of the syndrome [1]. LFS, also known as sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome, is a rare autosomal dominant hereditary disorder caused by mutations in different levels of TP53 germlines, a tumor suppressor gene that regulates the cell cycle. In some cases, the mutations can occur de novo, not from hereditary, and in 70%, they are due to mutations in TP53 [2–4].

In this syndrome, the literature is not enough to estimate a definite and universal prevalence. However, a recent study placed the prevalence of pathogenic and likely pathogenic germline TP53 variants in 1 : 3,555 to 1 : 5,476 on the general population [3]. Furthermore, advances in genomics report that LFS has 70% of genetic penetrance in males and 90% of that in females. This shows us a syndrome that requires careful monitoring of the family lineage [5, 6].

Epidemiological studies reveal that most patients with LFS develop primary cancer at a young age. The most prominent types of cancer associated with LFS are sarcomas, brain tumors, breast cancer, leukemia, and adrenal carcinoma. Other types of cancers associated with LFS include melanoma, lymphoma, renal tumors, laryngeal cancer, lung cancer, colon cancer, ovarian cancer, testicular cancer, and thyroid cancer [4, 6].

1. Introduction

Li–Fraumeni syndrome (LFS) was first reported in 1969 by Frederick Li and Joseph Fraumeni; hence, the name of the syndrome [1]. LFS, also known as sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome, is a rare autosomal dominant hereditary disorder caused by mutations in different levels of TP53 germlines, a tumor suppressor gene that regulates the cell cycle. In some cases, the mutations can occur de novo, not from hereditary, and in 70%, they are due to mutations in TP53 [2–4].

In this syndrome, the literature is not enough to estimate a definite and universal prevalence. However, a recent study placed the prevalence of pathogenic and likely pathogenic germline TP53 variants in 1 : 3,555 to 1 : 5,476 on the general population [3]. Furthermore, advances in genomics report that LFS has 70% of genetic penetrance in males and 90% of that in females. This shows us a syndrome that requires careful monitoring of the family lineage [5, 6].
hemiparesis, and progressive gait disturbance. No relevant pathological history is noted. During physical examination, the patient remained in a postictal state with neurological deterioration, memory impairment, and conduct disorder. There were also signs of intracranial hypertension. A CT was performed upon admission, which revealed a cystic lesion with irregular borders in the left parietal region that displaced the midline. Perilesional edema was also observed, as well as hydrocephalus (Figure 1). The lesion was surgically excised, revealing a 10 × 7 cm mass taken from the posterior horn of the lateral ventricle. An external ventricle shunt was put in place to maintain intracranial pressure. There were no intraoperative or postoperative complications.

Histopathological studies revealed a focal papillary neoplasia consistent with choroid plexus carcinoma (grade III). Due to the association of choroid plexus carcinomas with autosomal dominant germline mutations of the TP53 gene, the patient’s three-generation family history was reviewed. In the paternal side, multiple cases of liver and cervical cancers were discovered. The maternal side did not present a neoplastic history. Confirmatory pathological and immunohistochemical studies were performed at Saint Jude Children’s Research Hospital in Memphis, Tennessee, USA. The study reported the finding of a hypercellular neoplasm with pleomorphic tumors cells, mixed patterns of papillary and solid growth, and scattered mitotic activity. Additionally, immunohistochemical studies were positive for cytokine CAM 5.2 and p53, which strongly marked the nuclei of the tumor cells (Figure 2). These studies confirmed the presence of a TP53-mutant choroid plexus carcinoma.

The patient had a satisfactory course after surgical resection. Oncological follow-ups were carried out, with six cycles of chemotherapy (with ifosfamide, carboplatin, and etoposide). CT scan after the surgery revealed a subdural collection of approximately 134 ccs in the right frontotemporoparietal region (Figure 3). No remaining mass was observed, and the lateral ventricles were of standard size and
shape. According to the latest follow-up, the patient is asymptomatic, although he does refer to some loss of strength in the right side.

3. Discussion

TP53 is a vital gene because it maintains homeostasis at a molecular level, regulating the cell cycle through the encoding of the p53 protein, known as the "guardian of the genome" [7, 8]. Therefore, it is not surprising that any mutation in the TP53 gene would substantially impact the performance of cells and give rise to a variety of pathologies. A total of 200 polymorphisms associated with this gene have been identified today [7].

Although Li’s and Fraumeni’s first study began with 4 patients in 1969, by 1988, information of 24 different families was involved in the studies; 151 members of those families were diagnosed with some form of cancer. Because of this, a predictive pattern was observed and analyzed. The majority of these subjects had developed five types of cancer: sarcomas, breast cancer, leukemia, adrenal carcinoma, and brain tumors. Of the latter, a less common type was choroid plexus carcinoma. According to Tena-Suck et al., choroid plexus carcinoma represents only 0.3–0.6% of the tumors associated with the TP53 gene mutation [9]. According to this study and a similar study from St. Jude Children’s Hospital, patients under the age of 15 represent 2–4% of those diagnosed with choroid plexus carcinoma [10–12].

The annual incidence of choroid plexus carcinoma is 0.3/1,000,000 [10]. The WHO classifies choroid plexus tumors as grade I, choroid plexus papilloma; grade II, atypical choroid plexus papilloma; and grade III, choroid plexus carcinomas [13]. Choroid plexus papillomas represent 57.8% of all cases, while atypical choroid plexus papillomas represent 1.8% and choroid plexus carcinomas, 40% [11].

Several studies suggest that the rare appearance of choroid plexus tumors is associated with the TP53 gene mutations [14–16]. In this case, the patient had the tumor in the lateral ventricle, a region affected in 54% of patients with choroid plexus tumors. It is the most affected region because only 11% affects the third ventricle and 8%, the cerebellopontine angle [17].

Characteristic signs and symptoms (headache, hydrocephalus, gait disturbances, and projectile vomiting) are indicative of plexus choroid tumors, but not pathognomonic. The diagnosis is based on histopathological findings, with surgical excision playing an important role. As for the treatment of choroid plexus tumors, there is little evidence that fully supports a specific protocol. Tumor resection seems to be essential; however, only 30% of these tumors can be resected completely [18].

4. Conclusion

LFS is a rare pathology with high penetrance within family members that possess the TP53 gene mutation. Patients with LFS are at a higher risk of developing different types of cancer, namely, sarcomas, breast cancer, leukemia, adrenal carcinomas, and brain tumors. The definitive diagnosis is made with histopathological findings, particularly in the case of choroid plexus tumors. These tumors commonly affect younger patients, like the patient from this case. Treatment of choroid plexus tumors continues to be surgical resection, with adjuvant chemotherapy.

Data Availability

Patient file is stored at the statistics department of Hospital Mario Catarino Rivas.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

4

Case Reports in Pediatrics


